[go: up one dir, main page]

MX2009013682A - Enlazador de fmoc polimerico hidrolizable. - Google Patents

Enlazador de fmoc polimerico hidrolizable.

Info

Publication number
MX2009013682A
MX2009013682A MX2009013682A MX2009013682A MX2009013682A MX 2009013682 A MX2009013682 A MX 2009013682A MX 2009013682 A MX2009013682 A MX 2009013682A MX 2009013682 A MX2009013682 A MX 2009013682A MX 2009013682 A MX2009013682 A MX 2009013682A
Authority
MX
Mexico
Prior art keywords
linker
fmoc
hydrolysable polymeric
polymeric fmoc
hydrolysable
Prior art date
Application number
MX2009013682A
Other languages
English (en)
Inventor
Peter Turecek
Juergen Siekmann
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of MX2009013682A publication Critical patent/MX2009013682A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/164—Unsaturated ethers containing six-membered aromatic rings
    • C07C43/168—Unsaturated ethers containing six-membered aromatic rings containing six-membered aromatic rings and other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La invención se refiere a conjugados poliméricos a base de Fmoc (9-fluorenil-metoxicarbonilo) Estos conjugados son útiles para extender la circulación in vivo de fármacos de proteína y péptido.
MX2009013682A 2007-06-26 2008-06-25 Enlazador de fmoc polimerico hidrolizable. MX2009013682A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93716907P 2007-06-26 2007-06-26
US12326308P 2008-04-07 2008-04-07
PCT/EP2008/005155 WO2009000522A1 (en) 2007-06-26 2008-06-25 Hydrolysable polymeric fmoc-linker

Publications (1)

Publication Number Publication Date
MX2009013682A true MX2009013682A (es) 2010-08-31

Family

ID=39855055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013682A MX2009013682A (es) 2007-06-26 2008-06-25 Enlazador de fmoc polimerico hidrolizable.

Country Status (15)

Country Link
US (3) US7700551B2 (es)
EP (1) EP2173383B1 (es)
JP (1) JP5622569B2 (es)
KR (1) KR101654375B1 (es)
CN (1) CN101687048B (es)
AR (1) AR067627A1 (es)
AU (1) AU2008267360B2 (es)
BR (1) BRPI0813772A2 (es)
CA (1) CA2690554C (es)
DK (1) DK2173383T3 (es)
ES (1) ES2644453T3 (es)
MX (1) MX2009013682A (es)
NZ (1) NZ582669A (es)
TW (1) TWI569810B (es)
WO (1) WO2009000522A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
BRPI0813772A2 (pt) * 2007-06-26 2014-12-30 Baxter Int Composto, processo para a preparação de um composto, e, conjugado
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR101832937B1 (ko) 2009-07-27 2018-02-28 박스알타 인코퍼레이티드 혈액 응고 단백질 복합체
US9795683B2 (en) 2009-07-27 2017-10-24 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
WO2013010840A2 (en) 2011-07-18 2013-01-24 Arts Biologics A/S Long acting biologically active luteinizing hormone (lh) compound
US20150133383A1 (en) 2012-05-11 2015-05-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680295B1 (en) * 1994-09-22 2004-01-20 The Administrators Of The Tulane Educational Fund Method and pharmaceutical composition for prevention and treatment of brain damage
US6368814B1 (en) * 2000-12-22 2002-04-09 Roche Diagnostics Corporation Tricyclic antidepressant derivatives and immunoassay
WO2004089280A2 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
ES2294535T3 (es) * 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
JP4942014B2 (ja) * 2004-09-14 2012-05-30 独立行政法人産業技術総合研究所 Ｏ−結合型糖アミノ酸
BRPI0519562A2 (pt) * 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
MX2007016314A (es) * 2005-06-16 2008-03-10 Nektar Therapeutics Al Corp Conjugados que tienen un enlace degradable y reactivos polimericos utiles en la preparacion de tales conjugados.
AU2007333049B2 (en) * 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
WO2008082669A2 (en) * 2006-12-27 2008-07-10 Nektar Therapeutics Al, Corporation Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage
BRPI0813772A2 (pt) * 2007-06-26 2014-12-30 Baxter Int Composto, processo para a preparação de um composto, e, conjugado

Also Published As

Publication number Publication date
TWI569810B (zh) 2017-02-11
HK1142828A1 (en) 2010-12-17
US20090005542A1 (en) 2009-01-01
NZ582669A (en) 2011-07-29
AU2008267360B2 (en) 2013-09-12
CN101687048B (zh) 2013-02-27
EP2173383A1 (en) 2010-04-14
CN101687048A (zh) 2010-03-31
US20100121034A1 (en) 2010-05-13
US8445544B2 (en) 2013-05-21
JP5622569B2 (ja) 2014-11-12
DK2173383T3 (en) 2017-09-25
BRPI0813772A2 (pt) 2014-12-30
US20100121028A1 (en) 2010-05-13
ES2644453T3 (es) 2017-11-29
KR20100039854A (ko) 2010-04-16
TW200908996A (en) 2009-03-01
WO2009000522A1 (en) 2008-12-31
AU2008267360A1 (en) 2008-12-31
JP2010531371A (ja) 2010-09-24
AR067627A1 (es) 2009-10-21
EP2173383B1 (en) 2017-08-09
KR101654375B1 (ko) 2016-09-05
CA2690554A1 (en) 2008-12-31
CA2690554C (en) 2016-08-16
US7700551B2 (en) 2010-04-20

Similar Documents

Publication Publication Date Title
MX2009013682A (es) Enlazador de fmoc polimerico hidrolizable.
MY158325A (en) Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection
CY1122101T1 (el) Τροποποιημενα πολυπεπτιδια ρελαξινης και χρησεις αυτων
IL258724B (en) Modified fgf–21 polypeptides and their uses
MX350234B (es) Compuestos de enlace especificos de bacterias gram-positivas.
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MX2010005317A (es) Polipeptidos de insulina modificados y sus usos.
MX2012013375A (es) Peptido c pegilado.
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
TN2012000303A1 (en) Oxyntomodulin peptide analogue
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
UA118167C2 (uk) Пептид та його застосування
PH12012501263B1 (en) Oxyntomodulin peptide analogue
DE602008002693D1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
BRPI0811016A2 (pt) Proteína li truncada do papiloma vírus humano tipo 16
WO2008093058A3 (en) Peptides and their use
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
CY1114618T1 (el) Βιολογικα δραστικα πεπτιδια που περιεχουν καρβοξυτελικη αργινινη
EP2552462A4 (en) CCN3 THERAPEUTIC PEPTIDES AND THEIR ANALOGS
WO2012061113A3 (en) Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis
WO2012090207A3 (en) Par1 and par2 c-tail peptides and peptide mimetics
WO2010052243A3 (en) Neurotensin-derived branched peptides and uses thereof
EA201200889A1 (ru) Пептид

Legal Events

Date Code Title Description
FG Grant or registration